These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 1978516)

  • 21. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys.
    Akai T; Yamaguchi M; Mizuta E; Kuno S
    Ann Neurol; 1993 May; 33(5):507-11. PubMed ID: 8098931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys.
    Luquin MR; Obeso JA; Laguna J; Guillén J; Martínez-Lage JM
    Eur J Pharmacol; 1993 Apr; 235(2-3):297-300. PubMed ID: 7685291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1387-91. PubMed ID: 8099621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The visual system in Parkinson's disease.
    Bodis-Wollner I; Tagliati M
    Adv Neurol; 1993; 60():390-4. PubMed ID: 8420159
    [No Abstract]   [Full Text] [Related]  

  • 25. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism.
    Chiueh CC; Miyake H; Peng MT
    Adv Neurol; 1993; 60():251-8. PubMed ID: 8380519
    [No Abstract]   [Full Text] [Related]  

  • 26. MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects.
    Jenner P; Rose S; Nomoto M; Marsden CD
    Adv Neurol; 1987; 45():183-6. PubMed ID: 2881443
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
    Gomez-Mancilla B; Boucher R; Gagnon C; Di Paolo T; Markstein R; Bédard PJ
    Mov Disord; 1993 Apr; 8(2):144-50. PubMed ID: 8474480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
    D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
    Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys.
    Guttman M; Yong VW; Kim SU; Calne DB; Martin WR; Adam MJ; Ruth TJ
    Synapse; 1988; 2(5):469-73. PubMed ID: 3263709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
    Boireau A; Dubédat P; Bordier F; Peny C; Miquet JM; Durand G; Meunier M; Doble A
    Neuroreport; 1994 Dec; 5(18):2657-60. PubMed ID: 7696626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Operant behavioral disorders in monkeys with an MPTP-induced Parkinson-like syndrome].
    Burov IuV; Shul'govskiĭ VV; Petrov GV; Tereshchenko LV; Iudin AV
    Fiziol Zh Im I M Sechenova; 1995 Oct; 81(10):113-6. PubMed ID: 9026250
    [No Abstract]   [Full Text] [Related]  

  • 32. Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets.
    Rose S; Nomoto M; Jenner P; Marsden CD
    Biochem Pharmacol; 1989 Nov; 38(21):3677-81. PubMed ID: 2597167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.
    Bezard E; Stutzmann JM; Imbert C; Boraud T; Boireau A; Gross CE
    Eur J Pharmacol; 1998 Sep; 356(2-3):101-4. PubMed ID: 9774238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The partial dopamine receptor agonist terguride in the MPTP-induced hemiparkinsonian monkey model.
    Brücke T; Bankiewicz K; Harvey-White J; Kopin I
    Eur J Pharmacol; 1988 Apr; 148(3):445-8. PubMed ID: 3260191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nocturnal sleep structure and temperature slope in MPTP treated monkeys.
    Almirall H; Pigarev I; de la Calzada MD; Pigareva M; Herrero MT; Sagales T
    J Neural Transm (Vienna); 1999; 106(11-12):1125-34. PubMed ID: 10651108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MPTP induced hemiparkinsonism in monkeys: behavioral, mechanographic, electromyographic and immunohistochemical studies.
    Benazzouz A; Gross C; Dupont J; Bioulac B
    Exp Brain Res; 1992; 90(1):116-20. PubMed ID: 1355743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavioral tolerance to repeated apomorphine administration in parkinsonian monkeys.
    Luquin MR; Laguna J; Herrero MT; Obeso JA
    J Neurol Sci; 1993 Jan; 114(1):40-4. PubMed ID: 8094427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spinal cord metabolism of the 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkey.
    Schwartzman RJ; Alexander GM
    Brain Res; 1985 Jul; 337(2):263-8. PubMed ID: 3875382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys.
    Taylor JR; Lawrence MS; Redmond DE; Elsworth JD; Roth RH; Nichols DE; Mailman RB
    Eur J Pharmacol; 1991 Jul; 199(3):389-91. PubMed ID: 1680717
    [No Abstract]   [Full Text] [Related]  

  • 40. Dopamine fiber detection by [11C]-CFT and PET in a primate model of parkinsonism.
    Hantraye P; Brownell AL; Elmaleh D; Spealman RD; Wüllner U; Brownell GL; Madras BK; Isacson O
    Neuroreport; 1992 Mar; 3(3):265-8. PubMed ID: 1515582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.